89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

89bio, Inc. (ETNB) to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, showcasing their focus on innovative therapies for liver and cardiometabolic diseases. The webcast will be available on the company's website.

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the Oppenheimer 34^th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST and participate in one-on-one investor meetings.

The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Annie Chang 
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

Media Contact: 
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com

FAQ

What is the ticker symbol for 89bio, Inc.?

The ticker symbol for 89bio, Inc. is ETNB.

What is the focus of 89bio, Inc.?

89bio, Inc. is focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases.

When will 89bio, Inc. present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

89bio, Inc. will present at the conference on Tuesday, February 13, 2024 at 1:20 PM EST.

Where can the webcast of the presentation be accessed?

The webcast of the presentation will be accessible on the company's website and at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

What type of investor meetings will 89bio, Inc. participate in?

89bio, Inc. will participate in one-on-one investor meetings.

What is the focus of the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

The conference focuses on healthcare and life sciences, providing a platform for companies to present and engage with investors.